Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.42 |
| ▸ | NOS2 | P35228 | 1/20 | 0.42 |
| ▸ | ESR1 | P03372 | 1/20 | 0.34 |
| ▸ | SREBF1 | P36956 | 1/20 | 0.32 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | GPR84 | Q9NQS5 | 10/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | CDC7 | O00311 | 1/20 | 0.31 |
| ▸ | DBF4 | Q9UBU7 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10051193 | 0.83 | NOS3 (0.50) | NOS3NOS2ESR1ALDH1A1POLB | |
| SCHEMBL9310993 | 0.83 | NOS2 (0.46) | NOS3NOS2SREBF2ALDH1A1GPR84 | |
| SCHEMBL8545461 | 0.80 | SMN1; SMN2 (0.41) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL4273108 | 0.79 | NOS3 (0.39) | NOS3NOS2ESR1GPR84KDM5B | |
| SCHEMBL11070549 | 0.78 | — | — | |
| SCHEMBL11514418 | 0.78 | POLB (0.42) | ALDH1A1POLB | |
| SCHEMBL13827864 | 0.77 | NOS2 (0.57) | NOS3NOS2ESR1ALDH1A1SMN1; SMN2 | |
| SCHEMBL125608 | 0.77 | — | — | |
| SCHEMBL11514300 | 0.77 | ALDH1A1 (0.46) | ALDH1A1POLBSMN1; SMN2LMNA | |
| SCHEMBL20840536 | 0.77 | PRMT6 (0.31) | SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0326389-B1 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES (JP) | 1996-09-11 | — | — | EP | claimed |
| US-4935516-A | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | claimed |
| EP-0326389-A2 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1989-08-02 | — | — | EP | claimed |
| US-20250332155-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LTD (IN) | 2025-10-30 | — | — | US | disclosed |
| US-12377088-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE ONCOLOGY LIMITED (IN) | 2025-08-05 | — | — | US | disclosed |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE ONCOLOGY LIMITED (IN) | 2022-04-28 | — | — | US | disclosed |
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-01-25 | — | — | US | disclosed |
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2022-01-25 | — | — | US | disclosed |
| CN-113121497-A | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | 奥瑞基尼探索技术有限公司 | 2021-07-16 | — | — | CN | disclosed |
| EP-3845526-A1 | METHOD FOR THE PREPARATION OF TETRAHYDROQUINOLINONE COMPOUNDS HAVING ROR-GAMMA MODULATING ACTIVITY | Aurigene Discovery Technologies Limited (IN) | 2021-07-07 | — | — | EP | disclosed |
| WO-2016185342-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-11-24 | — | — | WO | disclosed |
| US-8188098-B2 | GPR119 receptor agonists | HOFFMANN-LA ROCHE INC. (US) | 2012-05-29 | — | — | US | disclosed |
| CN-102036991-A | GPR119 receptor agonists | HOFFMANN LA ROCHE | 2011-04-27 | — | — | CN | disclosed |
| EP-2283019-A1 | GPR119 RECEPTOR AGONISTS | F. Hoffmann-La Roche AG (CH) | 2011-02-16 | — | — | EP | disclosed |
| WO-2009141238-A1 | GPR119 RECEPTOR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-11-26 | — | — | WO | disclosed |
| US-20090286812-A1 | GPR119 Receptor Agonists | ERICKSON SHAWN DAVID | 2009-11-19 | — | — | US | disclosed |
| EP-0326389-B1 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES (JP) | 1996-09-11 | — | — | EP | disclosed |
| US-4935516-A | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1990-06-19 | — | — | US | disclosed |
| EP-0326389-A2 | Process for preparing 4-hydroxypyrimidine | UBE INDUSTRIES, LTD. (JP) | 1989-08-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377088-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | RORC, RORA, RORB | NOS3 3619/4885NOS2 3025/4885ESR1 1365/4885 |
| US-20250332155-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | NOS3 3619/4885NOS2 3025/4885ESR1 1365/4885 |
| US-20090286812-A1 | GPR119 Receptor Agonists | GPR119, GPR27, GPR139 | NOS3 2749/4885NOS2 2339/4885ESR1 368/4885 |
| US-11229636-B2 | Substituted tetrahydroquinolinone compounds as ROR gamma modulators | RORC, RORA, RORB | NOS3 3619/4885NOS2 3025/4885ESR1 1365/4885 |
| US-20220125780-A1 | SUBSTITUTED TETRAHYDROQUINOLINONE COMPOUNDS AS ROR GAMMA MODULATORS | RORC, RORA, RORB | NOS3 3619/4885NOS2 3025/4885ESR1 1365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.